Skip to main content
European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Psychiatric Ratings using Intermediate Stratified Markers 2

Descrizione del progetto

Biomarcatori innovativi per stratificare i disturbi neuropsichiatrici

La classificazione dei disturbi neuropsichiatrici quali la schizofrenia, in cui la biologia alla base rimane relativamente sconosciuta, dipende principalmente da biomarcatori di neuroimaging e da endpoint clinici. L’utilizzo di biomarcatori quantitativi non solo contribuirà alla classificazione delle malattie ma favorirà inoltre le attività di sviluppo dei farmaci. Il progetto PRISM 2, finanziato dall’UE, trarrà profitto dalle conoscenze generate dal suo progetto predecessore PRISM 1 nell’ambito di biomarcatori diagnostici e legati alle funzionalità sociali per la schizofrenia e il morbo di Alzheimer, con lo scopo di ampliarlo ai principali disturbi depressivi. L’obiettivo è individuare biomarcatori attendibili per agevolare la diagnosi e il trattamento personalizzato dei disturbi neuropsichiatrici.

Obiettivo

The current nosology of neuropsychiatric disorders provides a pragmatic approach to diagnosis and treatment choice but lacks reference to quantitative biological underpinnings of disease. This weakness impedes innovative drug development. To test whether a quantitative biological approach to the understanding and classification of neuropsychiatric disorders is both feasible and useful the PRISM 1 consortium was formed by academics, SMEs, patient organizations, regulators, ECNP, and EFPIA partners. PRISM 1 has now successfully identified quantitative biological parameters related to diagnosis (Schizophrenia (SZ) and Alzheimer Disease (AD)) as well as to social functioning irrespective of diagnosis. From the relationships between social function, neuroimaging, and cognitive endpoints a new neurobiological framework has emerged now needing further validation. Genetic studies of social functioning outcomes revealed known and novel loci for this phenotype. In addition, a preclinical test battery was developed, based on homologs of the clinical paradigms, to allow effective back-translation and a deepening of our neurobiological knowledge. Finally, a novel digital tool for assessing social function provided a novel, objective characterization that transcended the initial diagnostic classification and the digital readouts were associated with other study parameters. To build on outcomes of PRISM 1, PRISM 2 has three objectives. First, to determine the reproducibility of the transdiagnostic and pathophysiological relationship between DMN integrity and social dysfunction in SZ and AD that emerged from PRISM 1 and determine its potential to generalise to Major Depressive Disorders. Second, to test the causality between the quantitative variation in DMN integrity and social dysfunction. Third, to translate and communicate project results to the benefit of stakeholders, such as regulators, patients and their families, and health care providers.

Meccanismo di finanziamento

RIA - Research and Innovation action

Coordinatore

RIJKSUNIVERSITEIT GRONINGEN
Contribution nette de l'UE
€ 1 024 422,50
Indirizzo
Broerstraat 5
9712CP Groningen
Paesi Bassi

Mostra sulla mappa

Regione
Noord-Nederland Groningen Overig Groningen
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 1 624 422,50

Partecipanti (17)